Clinical Efficacy and Safety Evaluation of Xianling Gubao Capsule Treatment of Osteoporosis Pain

Objective: To investigate the clinical efficacy and safety evaluation of Xianling Gubao capsules on osteoporosis and to provide the basis for clinical treatment. Methods: During March 2012- March 2014 in our hospital,160 cases of osteoporosis pain patients were randomly divided into treatment groups based on a random number table( n = 80) and control group( n = 80). The control group was treated with Caltrate and the treatment group was treated with Xianling Gubao Capsule. Both groups were treated for six weeks as a course of treatment and after two course,we analyzed its clinical efficacy,bone density,blood and bone indicators of adverse reactions. Results: After treatment,lumbar spine BMD increased significantly and there was significant difference( P 0. 05). After treatment,lumbar spine BMD was significantly higher after treatment and there was significant difference( P 0. 05). After treatment,osteocalcin and β- collagen difference was statistically significant( P 0. 05). The osteocalcin after treatment was significantly higher and there was significant difference( P 0. 05). After treatment,β- collagen series were significantly lower than that of the control group after treatment and there was significant difference( P 0. 05). Two groups had no significant adverse reactions. Conclusion: Xianling Gubao capsule has significant clinical effect on patients with osteoporosis pain and can significantly relieve pain in patients and increase their osteocalcin levels and has no significant adverse reactions. The clinical application is safe,reliable and worthy of further research and promotion.